Filing Details

Accession Number:
0001140361-11-027096
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-05-12 18:59:22
Reporting Period:
2011-05-10
Filing Date:
2011-05-12
Accepted Time:
2011-05-12 18:59:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1124105 Targacept Inc TRGT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198177 Steven Burrill C/O Targacept, Inc.
200 East First Street, Suite 300
Winston-Salem NC 27101
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-05-10 16,948 $9.37 16,948 No 4 M Direct
Common Stock Disposition 2011-05-10 16,948 $24.04 0 No 4 S Direct
Common Stock Disposition 2011-05-10 2,000 $24.13 0 No 4 S Indirect By Burrill & Company LLC
Common Stock Acquisiton 2011-05-11 10,552 $9.37 10,552 No 4 M Direct
Common Stock Acquisiton 2011-05-11 7,500 $9.27 18,052 No 4 M Direct
Common Stock Acquisiton 2011-05-11 7,500 $7.10 25,552 No 4 M Direct
Common Stock Acquisiton 2011-05-11 7,500 $2.71 33,052 No 4 M Direct
Common Stock Disposition 2011-05-11 33,052 $23.88 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Indirect By Burrill & Company LLC
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2011-05-10 16,948 $0.00 16,948 $9.37
Common Stock Stock Option (Right to Buy) Disposition 2011-05-11 3,052 $0.00 3,052 $9.37
Common Stock Stock Option (Right to Buy) Disposition 2011-05-11 7,500 $0.00 7,500 $9.37
Common Stock Stock Option (Right to Buy) Disposition 2011-05-11 7,500 $0.00 7,500 $9.27
Common Stock Stock Option (Right to Buy) Disposition 2011-05-11 7,500 $0.00 7,500 $7.10
Common Stock Stock Option (Right to Buy) Disposition 2011-05-11 7,500 $0.00 7,500 $2.71
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,052 2007-05-14 2017-05-13 No 4 M Direct
0 2007-05-14 2017-05-13 No 4 M Direct
0 2007-06-12 2017-05-13 No 4 M Direct
0 2008-06-20 2017-06-19 No 4 M Direct
0 2009-06-09 2018-07-01 No 4 M Direct
0 2010-06-09 2019-06-16 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 0 Indirect By Burrill Biotechnology Capital Fund L.P.
Footnotes
  1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.99 to $24.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reporting person is the chief executive officer of Burrill & Company LLC. The reporting person disclaims beneficial ownership of securities owned by Burrill & Company LLC except to the extent of his pecuniary interest therein.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 to $24.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. Reflects a prior pro rata distribution by Burrill Biotechnology Capital Fund L.P. of all shares of the issuer previously reported as indirectly held by the reporting person as the managing member of Burrill & Company (Biotechnology GP), LLC, the general partner of Burrill Biotechnology Capital Fund L.P. The reporting person disclaims beneficial ownership of securities owned by Burrill Biotechnology Capital Fund L.P. except to the extent of his pecuniary interest therein.